Literature DB >> 19622403

Fanconi anemia and its diagnosis.

Arleen D Auerbach1.   

Abstract

Fanconi anemia (FA) is a genetically and phenotypically heterogeneous recessive disorder characterized by diverse congenital malformations, progressive pancytopenia, and predisposition to both hematologic malignancies and solid tumors. Congenital anomalies vary from patient to patient and may affect skeletal morphogenesis as well as any of the major organ systems. Although this highly variable phenotype makes accurate diagnosis on the basis of clinical manifestations difficult in some patients, laboratory study of chromosomal breakage induced by diepoxybutane (DEB) or other crosslinking agents provides a unique cellular marker for the diagnosis of the disorder either prenatally or postnatally. Diagnosis based on abnormal response to DNA crosslinking agents can be used to identify the pre-anemia patient as well as patients with aplastic anemia or leukemia who may or may not have the physical stigmata associated with the syndrome. This overview will present our current knowledge regarding the varied phenotypic manifestations of FA and procedures for diagnosis based upon abnormal DNA damage responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622403      PMCID: PMC2742943          DOI: 10.1016/j.mrfmmm.2009.01.013

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  33 in total

1.  Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance.

Authors:  J R Lo Ten Foe; M L Kwee; M A Rooimans; A B Oostra; A J Veerman; M van Weel; R M Pauli; N T Shahidi; I Dokal; I Roberts; C Altay; E Gluckman; R A Gibson; C G Mathew; F Arwert; H Joenje
Journal:  Eur J Hum Genet       Date:  1997 May-Jun       Impact factor: 4.246

2.  Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study.

Authors:  A P Gillio; P C Verlander; S D Batish; P F Giampietro; A D Auerbach
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

3.  Small pituitary size in children with Fanconi anemia.

Authors:  Rosa Sherafat-Kazemzadeh; Sanjeev N Mehta; Marguerite M Care; Mi-Ok Kim; David A Williams; Susan R Rose
Journal:  Pediatr Blood Cancer       Date:  2007-08       Impact factor: 3.167

4.  Fanconi anemia presenting unexpectedly in an adult kindred with no dysmorphic features.

Authors:  J M Liu; A D Auerbach; N S Young
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

5.  GST genotype may modify clinical phenotype in patients with Fanconi anaemia.

Authors:  Stella M Davies; Gretchen A Radloff; Todd E DeFor; Orna Levran; Sat Dev Batish; Helmut Hanenberg; Arleen D Auerbach
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

6.  Fanconi anemia diagnosis and the diepoxybutane (DEB) test.

Authors:  A D Auerbach
Journal:  Exp Hematol       Date:  1993-06       Impact factor: 3.084

7.  Fanconi anemia in brothers initially diagnosed with VACTERL association with hydrocephalus, and subsequently with Baller-Gerold syndrome.

Authors:  H C Rossbach; M J Sutcliffe; M M Haag; N H Grana; A R Rossi; J L Barbosa
Journal:  Am J Med Genet       Date:  1996-01-02

8.  Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study.

Authors:  P F Giampietro; P C Verlander; J G Davis; A D Auerbach
Journal:  Am J Med Genet       Date:  1997-01-10

9.  Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia.

Authors:  H Seyschab; R Friedl; Y Sun; D Schindler; H Hoehn; S Hentze; T Schroeder-Kurth
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

10.  Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study.

Authors:  A Butturini; R P Gale; P C Verlander; B Adler-Brecher; A P Gillio; A D Auerbach
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  200 in total

1.  Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance.

Authors:  James B Wilson; Eric Blom; Ryan Cunningham; Yuxuan Xiao; Gary M Kupfer; Nigel J Jones
Journal:  Mutat Res       Date:  2010-05-05       Impact factor: 2.433

2.  FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway.

Authors:  Abdullah Mahmood Ali; Arun Pradhan; Thiyam Ramsingh Singh; Changhu Du; Jie Li; Kebola Wahengbam; Elke Grassman; Arleen D Auerbach; Qishen Pang; Amom Ruhikanta Meetei
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

3.  Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair.

Authors:  Justin Wai Chung Leung; Yucai Wang; Ka Wing Fong; Michael Shing Yan Huen; Lei Li; Junjie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

4.  Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up.

Authors:  David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska
Journal:  Laryngoscope       Date:  2015-10-20       Impact factor: 3.325

Review 5.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Authors:  Mary Ellen Moynahan; Maria Jasin
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

6.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

7.  Normal red blood cells partially decrease diepoxybutane-induced chromosome breakage in cultured lymphocytes from Fanconi anaemia patients.

Authors:  B Porto; R Sousa; I Malheiro; J Gaspar; J Rueff; C Gonçalves; J Barbot
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

Review 8.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.

Authors:  Molly C Kottemann; Agata Smogorzewska
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

9.  Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice.

Authors:  Qing-Shuo Zhang; Weiliang Tang; Matthew Deater; Ngoc Phan; Andrea N Marcogliese; Hui Li; Muhsen Al-Dhalimy; Angela Major; Susan Olson; Raymond J Monnat; Markus Grompe
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

10.  Suppression of non-homologous end joining does not rescue DNA repair defects in Fanconi anemia patient cells.

Authors:  Supawat Thongthip; Brooke A Conti; Francis P Lach; Agata Smogorzewska
Journal:  Cell Cycle       Date:  2020-08-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.